alendronate has been researched along with Benign Neoplasms in 21 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized, double-blind, dose-ranging study of single-dose intravenous (IV) therapy with alendronate sodium (aminohydroxybutylidene bisphosphonate) was performed in patients with cancer-associated hypercalcemia." | 9.07 | Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. ( Averbuch, SD; Bilezikian, JP; Gertz, BJ; Glusman, J; Nussbaum, SR; Rude, R; Sacco, JF; Stepanavage, M; Stewart, AF; Warrell, RP, 1993) |
| "Cohort studies reporting association between alendronate or bisphosphonate therapy including alendronate in patients with osteoporosis and risk of cancer were selected by two authors." | 8.91 | The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies. ( Chen, LX; Cheng, L; Feng, SQ; Li, YL; Ning, GZ; Wu, QL; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "Controversy still exists regarding whether alendronate (ALN) use increases the risk of esophageal cancer or breast cancer." | 7.78 | A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study. ( Chang, SN; Kao, CH; Lee, WY; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2012) |
| "This study assessed the effectiveness and safety of denosumab (Prolia®) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs) (bazedoxifene, raloxifene) and placebo for the treatment of osteoporosis in hormone-sensitive cancer patients receiving endocrine therapy (men with prostate cancer [MPC] on hormone ablation therapy [HAT], and women with breast cancer [WBC] on adjuvant aromatase inhibitor therapy [AAIT])." | 5.41 | The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis ( Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T, 2023) |
| "A randomized, double-blind, dose-ranging study of single-dose intravenous (IV) therapy with alendronate sodium (aminohydroxybutylidene bisphosphonate) was performed in patients with cancer-associated hypercalcemia." | 5.07 | Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. ( Averbuch, SD; Bilezikian, JP; Gertz, BJ; Glusman, J; Nussbaum, SR; Rude, R; Sacco, JF; Stepanavage, M; Stewart, AF; Warrell, RP, 1993) |
| "Cohort studies reporting association between alendronate or bisphosphonate therapy including alendronate in patients with osteoporosis and risk of cancer were selected by two authors." | 4.91 | The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies. ( Chen, LX; Cheng, L; Feng, SQ; Li, YL; Ning, GZ; Wu, QL; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "We have found 11 cases of BRONJ in our hospital: 4 women taking oral alendronate or risendronate for osteoporosis and 7 cancer patients treated with intravenous zolendronic acid." | 4.88 | [Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces]. ( Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A, 2012) |
| "Controversy still exists regarding whether alendronate (ALN) use increases the risk of esophageal cancer or breast cancer." | 3.78 | A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study. ( Chang, SN; Kao, CH; Lee, WY; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2012) |
| " In this study we used a standardized ATP-based tumor chemosensitivity assay (ATP-TCA) to measure the activity of alendronate, clodronate and zoledronic acid in five ovarian carcinoma cell lines and human solid tumors (breast, lung, ovarian, unknown primary carcinoma, and cutaneous and uveal melanoma) (n=34)." | 3.73 | Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. ( Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M, 2005) |
| "Alendronate use was not associated with increased risk of cancer development in women with osteoporosis (adjusted hazard ratio, 1." | 1.38 | Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study. ( Chan, WL; Chen, JW; Chen, TJ; Chiang, CH; Chung, CM; Huang, CC; Huang, PH; Leu, HB; Lin, SJ, 2012) |
| "In vitro tests with breast cancer cells show that the γFe(2)O(3)@alendronate hybrid nanomaterial reduces cell viability and acts as a drug delivery system." | 1.37 | A multimodal magnetic resonance imaging nanoplatform for cancer theranostics. ( Benyettou, F; Chebbi, I; Di Benedetto, M; Lalatonne, Y; Lecouvey, M; Motte, L; Serfaty, JM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Nicolopoulos, K | 1 |
| Moshi, MR | 1 |
| Stringer, D | 1 |
| Ma, N | 1 |
| Jenal, M | 1 |
| Vreugdenburg, T | 1 |
| Kaur, S | 1 |
| Balakrishnan, B | 1 |
| Mallia, MB | 1 |
| Keshari, R | 1 |
| Hassan, PA | 1 |
| Banerjee, R | 1 |
| Hodgins, NO | 1 |
| Al-Jamal, WT | 1 |
| Wang, JT | 1 |
| Klippstein, R | 1 |
| Costa, PM | 1 |
| Sosabowski, JK | 1 |
| Marshall, JF | 1 |
| Maher, J | 1 |
| Al-Jamal, KT | 1 |
| Rajan, R | 1 |
| Sabnani, MK | 1 |
| Mavinkurve, V | 1 |
| Shmeeda, H | 1 |
| Mansouri, H | 1 |
| Bonkoungou, S | 1 |
| Le, AD | 1 |
| Wood, LM | 1 |
| Gabizon, AA | 1 |
| La-Beck, NM | 1 |
| Sahu, A | 1 |
| Hwang, Y | 1 |
| Vilos, C | 1 |
| Lim, JM | 1 |
| Kim, S | 1 |
| Choi, WI | 1 |
| Tae, G | 1 |
| Chen, LX | 1 |
| Ning, GZ | 1 |
| Zhou, ZR | 1 |
| Li, YL | 1 |
| Zhang, D | 1 |
| Wu, QL | 1 |
| Zhang, TS | 1 |
| Cheng, L | 1 |
| Feng, SQ | 1 |
| Chen, YC | 1 |
| Su, FM | 1 |
| Cheng, TT | 1 |
| Lai, HM | 1 |
| Yu, SF | 1 |
| O'Ryan, FS | 1 |
| Khoury, S | 1 |
| Liao, W | 1 |
| Han, MM | 1 |
| Hui, RL | 1 |
| Baer, D | 1 |
| Martin, D | 1 |
| Liberty, D | 1 |
| Lo, JC | 1 |
| Benyettou, F | 1 |
| Lalatonne, Y | 1 |
| Chebbi, I | 1 |
| Di Benedetto, M | 1 |
| Serfaty, JM | 1 |
| Lecouvey, M | 1 |
| Motte, L | 1 |
| Vestergaard, P | 1 |
| Schwartz, K | 1 |
| Rejnmark, L | 1 |
| Mosekilde, L | 1 |
| Pinholt, EM | 1 |
| Jacobsen, C | 1 |
| Metzler, P | 1 |
| Rössle, M | 1 |
| Obwegeser, J | 1 |
| Zemann, W | 1 |
| Grätz, KW | 1 |
| Chiang, CH | 1 |
| Huang, CC | 1 |
| Chan, WL | 1 |
| Huang, PH | 1 |
| Chen, TJ | 1 |
| Chung, CM | 1 |
| Lin, SJ | 1 |
| Chen, JW | 1 |
| Leu, HB | 1 |
| Arranz Caso, JA | 1 |
| Flores Ballester, E | 1 |
| Ngo Pombe, S | 1 |
| López Pizarro, V | 1 |
| Dominguez-Mompello, JL | 1 |
| Restoy Lozano, A | 1 |
| Lee, WY | 1 |
| Sun, LM | 1 |
| Lin, MC | 1 |
| Liang, JA | 1 |
| Chang, SN | 1 |
| Sung, FC | 1 |
| Muo, CH | 1 |
| Kao, CH | 1 |
| Andela, VB | 1 |
| Pirri, M | 1 |
| Schwarz, EM | 1 |
| Puzas, EJ | 1 |
| O'Keefe, RJ | 1 |
| Rosenblatt, JD | 1 |
| Rosier, RN | 1 |
| Knight, LA | 1 |
| Conroy, M | 1 |
| Fernando, A | 1 |
| Polak, M | 1 |
| Kurbacher, CM | 1 |
| Cree, IA | 1 |
| Budayr, AA | 1 |
| Zysset, E | 2 |
| Jenzer, A | 2 |
| Thiébaud, D | 1 |
| Ammann, P | 2 |
| Rizzoli, R | 3 |
| Jaquet-Müller, F | 2 |
| Bonjour, JP | 3 |
| Gertz, B | 1 |
| Burckhardt, P | 2 |
| Nussbaum, SR | 1 |
| Warrell, RP | 1 |
| Rude, R | 1 |
| Glusman, J | 1 |
| Bilezikian, JP | 1 |
| Stewart, AF | 1 |
| Stepanavage, M | 1 |
| Sacco, JF | 1 |
| Averbuch, SD | 1 |
| Gertz, BJ | 2 |
| Das, H | 1 |
| Wang, L | 1 |
| Kamath, A | 1 |
| Bukowski, JF | 1 |
| Portmann, L | 1 |
| Pryor-Tillotson, S | 1 |
| Buchs, B | 1 |
4 reviews available for alendronate and Benign Neoplasms
| Article | Year |
|---|---|
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Horm | 2023 |
The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Colorectal Neoplasms; Female; Humans; | 2015 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphon | 2012 |
The mevalonate synthesis pathway as a therapeutic target in cancer.
Topics: Acute-Phase Proteins; Alendronate; Alkyl and Aryl Transferases; Animals; Dose-Response Relationship, | 2003 |
3 trials available for alendronate and Benign Neoplasms
| Article | Year |
|---|---|
Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Analysis of Variance; Diphosphonates; Dose-Response Rel | 1993 |
Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Doub | 1992 |
Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate.
Topics: Aged; Alendronate; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Dose-Response Relations | 1992 |
14 other studies available for alendronate and Benign Neoplasms
| Article | Year |
|---|---|
Technetium-99m labeled core shell hyaluronate nanoparticles as tumor responsive, metastatic skeletal lesion targeted combinatorial theranostics.
Topics: Alendronate; Cell Line, Tumor; Glycosaminoglycans; Humans; Nanoparticles; Neoplasms; Palmitic Acid; | 2023 |
Investigating in vitro and in vivo αvβ6 integrin receptor-targeting liposomal alendronate for combinatory γδ T cell immunotherapy.
Topics: Alendronate; Animals; Antigens, Neoplasm; Cell Line, Tumor; Cell Survival; Female; Humans; Immunothe | 2017 |
Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.
Topics: Alendronate; Animals; Cell Line, Tumor; Female; Immune Tolerance; Liposomes; Macrophages; Male; Mice | 2018 |
A novel alendronate functionalized nanoprobe for simple colorimetric detection of cancer-associated hypercalcemia.
Topics: Alendronate; Animals; Calcium; Colorimetry; Female; Gold; Hypercalcemia; Metal Nanoparticles; Mice; | 2018 |
Is Long-Term Anti-Osteoporotic Treatment Associated with Greater Risk of Cancer in People with Severe Vertebral Fractures? A Hospital-Based Cohort Study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Female; Hospitaliza | 2015 |
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis | 2009 |
A multimodal magnetic resonance imaging nanoplatform for cancer theranostics.
Topics: Alendronate; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Contrast Media; Dru | 2011 |
Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
Topics: Administration, Oral; Aged; Alcoholism; Alendronate; Bisphosphonate-Associated Osteonecrosis of the | 2012 |
Osteopathology induced by bisphosphonates and dental implants: clinical observations.
Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents | 2013 |
Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study.
Topics: Administration, Oral; Aged; Alendronate; Case-Control Studies; Female; Follow-Up Studies; Humans; In | 2012 |
A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Coh | 2012 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemoth | 2005 |
Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Topics: Alendronate; Calcitriol; Calcium; Creatinine; Diphosphonates; Female; Humans; Hypercalcemia; Male; N | 1994 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic | 2001 |